Shares of Biocon fell on Friday, March 27, after Siddharth Mittal resigned as CEO and MD, who will transition to a new role ...

Biocon share price has rallied over 20% in one month and has gained 17% in three months. The stock has surged 28% in six ...

The leadership transition is part of the full integration of Biocon Biologics Ltd. as a wholly-owned subsidiary of Biocon Ltd ...

A sharp sell-off gripped Dalal Street as the benchmark indices plunged. Equity markets witnessed a sharp correction today after the fresh comments from US President dashed hopes of a near term ...

I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026.

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon (BION.NS), opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S ...

The Bengaluru-based drugmaker has approvals for biosimilar versions of Insulin Glargine, Insulin Aspart and Human Insulin.

As Biocon prepares for a leadership transition on April 1, newly designated CEO and MD Shreehas Tambe has outlined a ...

In Biocon’s continuing effort to divest and Eris Lifesciences’ attempt to grow, the companies have expanded a previous agreement, with Bangalore-based generics giant Biocon selling Indian branded ...